Presented by: Alan P. Agins, Ph.D. & Jody Agins, MSN, RNP, FNP/GNP-BC
A continuing education program for nurse practitioners and RNs approved for 2.0 contact hours of pharmacology
Release Date: December 1, 2016
Expiration Date: November 30, 2019
The Nurse Practitioner Healthcare Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analagesic REMS Program Companies.
Requirements for successful completion of this CNE activity include downloading the handout (after registering), viewing all video segments, answering the assessment questions embedded within the program and completing an online program evaluation. There is no partial credit.
Faculty / Planner Disclosures
The information presented in this program is solely for educational purposes and should not be construed as specific instructions for the diagnosis or treatment of patients. Utilization of any information, derived from this program, in patient care remains strictly the professional responsibility of the health care provider. The health care provider is further advised to: (1) ascertain current FDA status of each drug and (2) consult current drug information guides, manufacturer product information or package inserts regarding the proper use, dosages, dosing schedules, contraindications, warnings and other pertinent prescribing and safety information. The Faculty (Alan Agins amd Jody Agins) disclaim any liability, loss, injury or damage incurred as a consequence, directly or indirectly, from the use and application of any of the contents of this program. During the "Program" there may be occasional mention of proprietary or brand-name drugs. The mention or appearance of a specific proprietary product name should not be construed by the viewer that the Faculty, NPHF or CO*RE endorse or have specific bias toward that product or its manufacturer. Similarly, the absence of mention of a specific brand name should not imply that the product is deemed inferior to others in its class